Onward Therapeutics, Inc.
Onward Therapeutics Closes NT$900 Million (approximately US$28 Million) Series B Financing to Advance Clinical-Stage Oncology Pipeline
First capital increase since relocating global headquarters to Taiwan; Company targets Emerging Stock Board registration by the end of 2027 TAIPEI…
